Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 24, 2026, 7:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD) Clear all

Conditions: Asthma, Reactive Airway Disease
Interventions: Dexamethasone, Prednisone; Drug
Lead sponsor: Alameda County Medical Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Oakland, California

Conditions: Chronic Obstructive Pulmonary Disease, COPD
Interventions: Ramelteon and Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 21 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 6
States / cities: Birmingham, Alabama • Santa Monica, California • Miami Beach, Florida + 3 more

Conditions: COPD
Interventions: Racemic formoterol, Arformoterol tartrate inhalation solution; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 35 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 6
States / cities: Long Beach, California • Fort Lauderdale, Florida • Raleigh, North Carolina + 3 more

Conditions: COPD, Smoking, Tobacco Use
Interventions: THS use, Cigarette, Smoking Abstinence; Other
Lead sponsor: Philip Morris Products S.A.; Industry
Eligibility: 35 Years to 65 Years
Enrollment: 715 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 81
States / cities: Brandon, Florida • Cape Coral, Florida • Clearwater, Florida + 41 more

Conditions: Safety and Tolerability
Interventions: inhaled human insulin, Insulin Lispro (Humalog U-100); Drug
Lead sponsor: Dance Biopharm Inc.; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Cypress, California

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Danirixin 35 mg tablets, Placebo, Metered dose inhaler (MDI) sensor device, Rescue medication; Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 76 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 11
States / cities: Birmingham, Alabama • San Diego, California • Torrance, California + 8 more

Conditions: Smoking Cessation
Interventions: placebo, Varenicline Tartarate; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 35 Years and older
Enrollment: 504 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 15 more

Conditions: Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
Interventions: GSP304 (tiotropium bromide) Inhalation Solution, GSP304 Placebo Inhalation Solution, Spiriva® Respimat® inhalation spray; Drug
Lead sponsor: Glenmark Specialty S.A.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 25
States / cities: Andalusia, Alabama • Phoenix, Arizona • Tempe, Arizona + 18 more

Conditions: COPD, Dyspnea, Respiratory Disease, Lung Diseases
Interventions: Fluoroscopy; Radiation
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 30 Years to 85 Years
Enrollment: 15 participants
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Danirixin, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 6
States / cities: Birmingham, Alabama • Denver, Colorado • Iowa City, Iowa + 3 more

Conditions: Asthma, COPD (Chronic Obstructive Pulmonary Disease)
Interventions: GB-0895 (SC), Placebo (SC); Biological · Drug
Lead sponsor: Generate Biomedicines; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 6
States / cities: DeLand, Florida • Miami, Florida • Orlando, Florida + 3 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Inhaled PT001, Inhaled Placebo, Tiotropium Handihaler; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 6
States / cities: Peoria, Arizona • Denver, Colorado • Miami, Florida + 3 more

Conditions: COPD
Interventions: QAB149; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 2
States / cities: Encinitas, California • Boise, Idaho

Search by objective public record fields.

Single Oral Dose of Dexamethasone Versus Five Days of Prednisone in Adult Asthma

Safety of Ramelteon in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease

Study of Arformoterol Tartrate Inhalation Solution and Racemic Formoterol in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)

Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms.

PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD

A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)

Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).

Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Ventilation Imbalances in Mild to Moderate Chronic Obstructive Pulmonary Disease

Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations

A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD

Study to Evaluate the Safety and Efficacy of Inhaled PT001 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD)